Skip to main content
. 2020 Jan 14;2020:3283940. doi: 10.1155/2020/3283940

Table 2.

Treatment outcomes.

Conservative treatment (n = 137) Urgent hemostasis (n = 5) P-value
Hemostasis 137 (100%) 5 (100%)
Mortality
 Bleeding 0 (0%) 0 (0%) 0.978
 Others 1 (0.7%) 0 (0%)
Blood transfusion 60 (43.8%) 5 (100%) 0.003
 Units of blood (mean ± SD) 2.7 ± 4.0 10.0 ± 3.3 0.0002
 Hb level during transfusion (g/dL, mean ± SD) 7.2 ± 1.3 7.0 ± 1.5
Hemorrhagic shock (systolic BP < 90 mmHg) 11 (8.0%) 5 (100%) <0.0001
Periods of fasting (days, mean ± SD) 4.1 ± 1.7 (1–9) 4.8 ± 1.9 (4–7) 0.342
Length of hospitalization (days, mean ± SD) 11.3 ± 5.9 (3–34) 19.2 ± 21.4 (9–30) 0.040
Hospitalization costs (USD, mean ± SD) 4270.68 ± 2452.30 8237.28 ± 3211.87
7169.06 ± 2168.09∗∗
0.0001
0.047
Early rebleeding 10 (7.3%)∗∗∗ 0 (0%) 0.690
Recurrent bleeding 29 (22.7%) 1 (20%) 0.685

SD, standard deviation; Hb, hemoglobin; BP, blood pressure; USD, the United States dollar. Three of five patients underwent endoscopic hemostasis, and the other two patients underwent transcatheter arterial embolization, resulting in successful hemostasis in all patients. ∗∗Except the two patients who received interventional radiology treatment, ∗∗∗all patients achieved spontaneous hemostasis after early rebleeding.